Identification of gene polymorphisms that predict the efficacy and safety of nivolumab treatment for renal cancer
Not Applicable
Recruiting
- Conditions
- Renal cell cancer
- Registration Number
- JPRN-UMIN000037739
- Lead Sponsor
- Graduate School of Medical Sciences, Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1.non-Japanese patients 2.Patients in whom the evaluation of response rate according to RECIST ver.1.1 is not carried out within 24 weeks after the start of treatment 3.Patients who received nivolumab as first line treatment 4.Patients who co-administered with drugs for renal cancer other than nivolumab 5.Patients who are judged inappropriate for participation in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SNPs that correlate with tumor response to nivolumab
- Secondary Outcome Measures
Name Time Method SNPs that correlate with progression , treatment continuation and overall survival in nivolumab treatment SNPs that correlate with adverse events in nivolumab treatment